Tezspire

Chemical Nametezepelumab-ekko
Dosage FormInjection (subcutaneous; 210 mg/1.91 mL (110 mg/mL))
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyAmgen
Approval Year2021

Indication

  • For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tezspire (tezepelumab-ekko) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA
Document TitleYearSource
Tezepelumab for severe asthma. 2021ICER